ICON and Empire Genomics Partner for the Delivery of Personalized Medicine Services
and
Empire Genomics
announced the formation of a strategic alliance.
ICON and Empire Genomics will partner to develop a service portfolio tailored to the development of personalized medicines. The partnership combines Empire Genomics’ expertise in pharmacogenomics, computational modeling of disease state, drug disposition and drug targets with ICON’s expertise in translational medicine, clinical trial design, and biomarkers. The combined service offering will enable the identification of responder target populations, permit the stratification of patients through the development and use of companion diagnostics and will streamline drug development programs through the generation and analysis of relevant data obtained in the pre-clinical and early stage clinical setting.
“We look to partner with companies, scientists, and research institutions that complement our corporate strategies and experience, and this collaboration gives us the opportunity to work with industry leading clinical units, translational medicine expertise, and the broader ICON full-service offering,” commented Anthony Johnson, Chief Executive Officer, Empire Genomics.
“Genomics plays an integral role in personalized medicine, and through our collaboration with Empire Genomics, we can now offer sponsors integrated personalized medicine services,” commented Dr. Cyril Clarke, Vice President Translational Medicine, ICON Development Solutions. “We believe that this partnership will help sponsors to speed development by enhancing target population identification to ultimately produce safer, more effective medicines.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
